Literature DB >> 29685716

Homocysteine and Incident Atrial Fibrillation: The Atherosclerosis Risk in Communities Study and the Multi-Ethnic Study of Atherosclerosis.

Yasuhiko Kubota1, Alvaro Alonso2, Susan R Heckbert3, Faye L Norby4, Aaron R Folsom4.   

Abstract

BACKGROUND: Although many studies have investigated the association of blood homocysteine with major cardiovascular diseases such as coronary heart disease and stroke, research on its association with atrial fibrillation (AF) is scarce.
METHODS: We analysed data from Atherosclerosis Risk in Communities (ARIC) Study (n=492, age 45-64 years) and Multi-Ethnic Study of Atherosclerosis (MESA) (n=6,641, age 45-84 years).
RESULTS: During the 10,106 and 67,613 person-years of follow-up, we identified 85 and 351 AF events in ARIC and MESA, respectively. An age-, sex-, and race-adjusted model showed dose-response relations between plasma homocysteine concentrations and AF incidence in both ARIC and MESA. Further adjustments for other AF risk factors did not change the associations. In the fully adjusted model, a meta-analysis of both studies showed a significant association between homocysteine and AF [hazard ratio (95% confidence interval) per 1 unit increment in log2(homocysteine), 1.27 (1.01-1.61)]. Individuals with higher levels of all three B vitamins (vitamin B6 and B12, and folate) had a lower risk of AF, but those associations were not statistically significant. In the full ARIC cohort [n=12,686 (2079 AF events)], there was no association between the C677T methylenetetrahydrofolate reductase (MTHFR) mutation and AF.
CONCLUSIONS: In the prospective population-based ARIC and MESA cohorts, elevated homocysteine was modestly associated with an increased risk of incident AF, but the C677T MTHFR mutation was not associated with AF risk, suggesting that homocysteine may be a novel risk marker for AF rather than a causal risk factor.
Copyright © 2018 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; General population; Homocysteine; Prospective study

Mesh:

Substances:

Year:  2018        PMID: 29685716      PMCID: PMC6150836          DOI: 10.1016/j.hlc.2018.03.007

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  44 in total

1.  Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels.

Authors:  S Friso; P F Jacques; P W Wilson; I H Rosenberg; J Selhub
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

2.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

Review 3.  Homocysteine and cardiovascular disease: cause or effect?

Authors:  L Brattström; D E Wilcken
Journal:  Am J Clin Nutr       Date:  2000-08       Impact factor: 7.045

4.  Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation?

Authors:  Rossella Marcucci; Irene Betti; Emanuele Cecchi; Daniela Poli; Betti Giusti; Sandra Fedi; Ilaria Lapini; Rosanna Abbate; Gian Franco Gensini; Domenico Prisco
Journal:  Am Heart J       Date:  2004-09       Impact factor: 4.749

5.  B vitamin status and inflammatory markers.

Authors:  Aaron R Folsom; Moïse Desvarieux; F Javier Nieto; Lori L Boland; Christie M Ballantyne; Lloyd E Chambless
Journal:  Atherosclerosis       Date:  2003-07       Impact factor: 5.162

6.  Homocysteine lowering with folic acid and B vitamins in vascular disease.

Authors:  Eva Lonn; Salim Yusuf; Malcolm J Arnold; Patrick Sheridan; Janice Pogue; Mary Micks; Matthew J McQueen; Jeffrey Probstfield; George Fodor; Claes Held; Jacques Genest
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

7.  Homocysteine lowering and cardiovascular events after acute myocardial infarction.

Authors:  Kaare Harald Bønaa; Inger Njølstad; Per Magne Ueland; Henrik Schirmer; Aage Tverdal; Terje Steigen; Harald Wang; Jan Erik Nordrehaug; Egil Arnesen; Knut Rasmussen
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

8.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

9.  Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction.

Authors:  Ramachandran S Vasan; Alexa Beiser; Ralph B D'Agostino; Daniel Levy; Jacob Selhub; Paul F Jacques; Irwin H Rosenberg; Peter W F Wilson
Journal:  JAMA       Date:  2003-03-12       Impact factor: 56.272

10.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

View more
  7 in total

1.  Choline Metabolism and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Study.

Authors:  Christopher Papandreou; Mònica Bulló; Pablo Hernández-Alonso; Miguel Ruiz-Canela; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary Clish; Dolores Corella; Ramon Estruch; Emilio Ros; Montserrat Fitó; Angel Alonso-Gómez; Miquel Fiol; José M Santos-Lozano; Lluís Serra-Majem; Liming Liang; Miguel A Martínez-González; Frank B Hu; Jordi Salas-Salvadó
Journal:  Clin Chem       Date:  2021-01-08       Impact factor: 8.327

2.  Serum Homocysteine Level Predictive Capability for Severity of Restenosis Post Percutaneous Coronary Intervention.

Authors:  Jiqiang Guo; Ying Gao; Mohammad Ahmed; Pengfei Dong; Yuping Gao; Zhihua Gong; Jinwen Liu; Yajie Mao; Zhijie Yue; Qingli Zheng; Jiansheng Li; Jianrong Rong; Yongnian Zhou; Meiwen An; Linxia Gu; Jin Zhang
Journal:  Front Pharmacol       Date:  2022-05-24       Impact factor: 5.988

3.  Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors.

Authors:  Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet
Journal:  Metabolism       Date:  2021-01-07       Impact factor: 8.694

4.  Mitochondria-derived methylmalonic acid, a surrogate biomarker of mitochondrial dysfunction and oxidative stress, predicts all-cause and cardiovascular mortality in the general population.

Authors:  Shanjie Wang; Yige Liu; Jinxin Liu; Wei Tian; Xiaoyuan Zhang; Hengxuan Cai; Shaohong Fang; Bo Yu
Journal:  Redox Biol       Date:  2020-09-30       Impact factor: 11.799

5.  Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation.

Authors:  Denise M S van Marion; Eva A H Lanters; Kennedy S Ramos; Jin Li; Marit Wiersma; Luciënne Baks-Te Bulte; Agnes J Q M Muskens; Eric Boersma; Natasja M S de Groot; Bianca J J M Brundel
Journal:  Cells       Date:  2020-09-16       Impact factor: 6.600

6.  Appraising the Causal Association of Plasma Homocysteine Levels With Atrial Fibrillation Risk: A Two-Sample Mendelian Randomization Study.

Authors:  Songzan Chen; Fangkun Yang; Tian Xu; Yao Wang; Kaijie Zhang; Guosheng Fu; Wenbin Zhang
Journal:  Front Genet       Date:  2021-05-26       Impact factor: 4.599

7.  Association Between Homocysteine and Vascular Calcification Incidence, Prevalence, and Progression in the MESA Cohort.

Authors:  Amy B Karger; Brian T Steffen; Sarah O Nomura; Weihua Guan; Parveen K Garg; Moyses Szklo; Matthew J Budoff; Michael Y Tsai
Journal:  J Am Heart Assoc       Date:  2020-01-30       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.